Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005858 · ClinicalTrials.gov registry record · Phase 1
LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-small Cell Lung, Bladder, Pancreatic, or Ovarian Cancer
A Phase 1 study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT00005858 is a Phase 1 study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 25 participants.
The verdict
NCT00005858, a Phase 1 study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
Phase I trial to study the effectiveness of LMB-9 immunotoxin in treating patients who have advanced colon, breast, non-small cell lung, bladder, pancreatic, or ovarian cancer. The LMB-9 immunotoxin can locate tumor cells and kill them without harming normal cells.
Interventions
- BIOLOGICAL LMB-9 immunotoxin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2000-04 |
| Est. Completion | 2003-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005858
The ClinicalTrials.gov registry entry for NCT00005858 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LMB-9 immunotoxin is the first listed.
NCT00005858 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005858 about?
NCT00005858 is a clinical study titled "LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-small Cell Lung, Bladder, Pancreatic, or Ovarian Cancer". Phase I trial to study the effectiveness of LMB-9 immunotoxin in treating patients who have advanced colon, breast, non-small cell lung, bladder, pancreatic, or ovarian cancer. The LMB-9 immunotoxin can locate tumor cells and kill them without harming normal cells.
What is the current status of trial NCT00005858?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2000-04. Estimated completion is 2003-12.
What interventions are being tested in trial NCT00005858?
The interventions under investigation include: LMB-9 immunotoxin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00005858?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.